The back-to-back cardiovascular setbacks at Novartis and Novo Nordisk have shifted attention from the promise of lipoprotein(a) lowering to the evidence gap still facing the field.
Just before Labor Day, Novartis said pelacarsen failed in a widely watched, seven-year clinical trial. The drug was designed to reduce the rates of heart attack or stroke by lowering lipoprotein(a), or Lp(a), a type of lipid that, at elevated concentrations, increases the likelihood of severe heart problems. An estimated 20% of people have abnormally high levels.
The Data Point That Matters
Pelacarsen was the first stab at a new type of cardiovascular treatment. Its failure therefore carries more weight than a routine single-asset miss, because it tests whether changing Lp(a) translates into the clinical benefit investors and companies had been modeling.
The source report notes that multiple other drug companies have invested billions of dollars in their own Lp(a) medicines. That makes Novartis’ result relevant beyond one program: the disappointment lands in a disease area where valuation, partnering logic, and pipeline narratives were built around the assumption that lowering the biomarker would also lower major cardiovascular events.
The Field-Level Impact
The immediate effect is likely to be a tougher environment for companies pursuing the same biology. The source report says the recent failures could have a chilling effect across the industry and likely “pop a hole in the balloon” of the field.
That does not prove the target is invalid, and it does not settle whether different modalities or patient selections could perform better. But it does change the commercial threshold. After a seven-year study missed, future Lp(a) programs may face more skepticism from investors and a higher evidentiary bar if they want to argue that biomarker reduction alone is enough to support the broader thesis.
